Compare CEPU & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPU | STOK |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2017 | 2019 |
| Metric | CEPU | STOK |
|---|---|---|
| Price | $14.33 | $29.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $17.50 | ★ $39.20 |
| AVG Volume (30 Days) | 250.3K | ★ 1.0M |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | N/A | $77.49 |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $7.43 | $12.25 |
| 52 Week High | $18.50 | $40.22 |
| Indicator | CEPU | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 38.38 |
| Support Level | $13.87 | $28.22 |
| Resistance Level | $16.45 | $33.51 |
| Average True Range (ATR) | 0.57 | 1.56 |
| MACD | -0.04 | -0.38 |
| Stochastic Oscillator | 20.42 | 12.29 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.